Soleno Therapeutics (SLNO) Competitors $59.21 +1.23 (+2.12%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$58.52 -0.69 (-1.16%) As of 10/3/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SLNO vs. FEMY, IMVT, PEN, STVN, IRTC, BLCO, GKOS, TMDX, NVST, and LIVNShould you be buying Soleno Therapeutics stock or one of its competitors? The main competitors of Soleno Therapeutics include Femasys (FEMY), Immunovant (IMVT), Penumbra (PEN), Stevanato Group (STVN), iRhythm Technologies (IRTC), Bausch + Lomb (BLCO), Glaukos (GKOS), TransMedics Group (TMDX), Envista (NVST), and LivaNova (LIVN). These companies are all part of the "medical" sector. Soleno Therapeutics vs. Its Competitors Femasys Immunovant Penumbra Stevanato Group iRhythm Technologies Bausch + Lomb Glaukos TransMedics Group Envista LivaNova Soleno Therapeutics (NASDAQ:SLNO) and Femasys (NASDAQ:FEMY) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership, earnings and profitability. Do analysts recommend SLNO or FEMY? Soleno Therapeutics currently has a consensus price target of $115.09, suggesting a potential upside of 94.38%. Femasys has a consensus price target of $7.33, suggesting a potential upside of 1,063.84%. Given Femasys' higher possible upside, analysts plainly believe Femasys is more favorable than Soleno Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Soleno Therapeutics 1 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.92Femasys 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has stronger valuation and earnings, SLNO or FEMY? Femasys has higher revenue and earnings than Soleno Therapeutics. Soleno Therapeutics is trading at a lower price-to-earnings ratio than Femasys, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSoleno TherapeuticsN/AN/A-$175.85M-$4.14-14.30Femasys$1.63M12.59-$18.82M-$0.86-0.73 Do institutionals and insiders hold more shares of SLNO or FEMY? 97.4% of Soleno Therapeutics shares are held by institutional investors. Comparatively, 65.3% of Femasys shares are held by institutional investors. 6.4% of Soleno Therapeutics shares are held by company insiders. Comparatively, 11.5% of Femasys shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the media refer more to SLNO or FEMY? In the previous week, Soleno Therapeutics had 6 more articles in the media than Femasys. MarketBeat recorded 7 mentions for Soleno Therapeutics and 1 mentions for Femasys. Soleno Therapeutics' average media sentiment score of 0.00 equaled Femasys'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Soleno Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Femasys 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility and risk, SLNO or FEMY? Soleno Therapeutics has a beta of -2.75, meaning that its stock price is 375% less volatile than the S&P 500. Comparatively, Femasys has a beta of -2.64, meaning that its stock price is 364% less volatile than the S&P 500. Is SLNO or FEMY more profitable? Soleno Therapeutics has a net margin of 0.00% compared to Femasys' net margin of -1,113.72%. Soleno Therapeutics' return on equity of -73.74% beat Femasys' return on equity.Company Net Margins Return on Equity Return on Assets Soleno TherapeuticsN/A -73.74% -56.67% Femasys -1,113.72%-713.74%-152.60% SummarySoleno Therapeutics beats Femasys on 8 of the 15 factors compared between the two stocks. Get Soleno Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SLNO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SLNO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SLNO vs. The Competition Export to ExcelMetricSoleno TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.15B$2.63B$6.13B$10.58BDividend YieldN/A56.38%5.66%4.69%P/E Ratio-14.3024.2286.8826.70Price / SalesN/A738.76608.05229.32Price / CashN/A28.3526.3031.09Price / Book10.425.3112.536.57Net Income-$175.85M$32.78M$3.30B$276.78M7 Day Performance-8.85%3.90%4.28%2.42%1 Month Performance-15.14%8.79%6.90%8.63%1 Year Performance19.30%-3.79%70.54%31.60% Soleno Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SLNOSoleno Therapeutics4.178 of 5 stars$59.21+2.1%$115.09+94.4%+19.3%$3.15BN/A-14.3030FEMYFemasys2.5798 of 5 stars$0.36+3.3%$7.33+1,929.1%-43.2%$11.40M$1.63M-0.4230Analyst UpgradeGap UpIMVTImmunovant1.8947 of 5 stars$15.59+5.5%$33.60+115.5%-44.6%$2.58BN/A-5.47120Analyst ForecastPENPenumbra4.6866 of 5 stars$254.79-0.3%$302.93+18.9%+31.5%$9.97B$1.19B67.764,500News CoverageAnalyst ForecastInsider TradeSTVNStevanato GroupN/A€27.01+0.8%N/A+37.3%€8.18B€1.19B50.025,521Gap UpIRTCiRhythm Technologies1.1473 of 5 stars$184.73+5.5%$163.82-11.3%+180.0%$5.62B$591.84M-63.052,000Analyst ForecastBLCOBausch + Lomb1.8778 of 5 stars$15.26+0.5%$15.56+1.9%-20.1%$5.38B$4.79B-19.5613,500News CoverageAnalyst ForecastGKOSGlaukos4.5685 of 5 stars$84.74+1.5%$123.58+45.8%-33.2%$4.79B$383.48M-51.36780Analyst ForecastTMDXTransMedics Group3.2436 of 5 stars$125.15+2.3%$125.40+0.2%-16.8%$4.17B$441.54M64.84210Positive NewsNVSTEnvista3.6888 of 5 stars$20.90-0.1%$20.92+0.1%+10.7%$3.48B$2.51B65.3212,300LIVNLivaNova2.3175 of 5 stars$55.13+0.2%$59.71+8.3%-0.9%$3.00B$1.25B-14.172,900Analyst Downgrade Related Companies and Tools Related Companies Femasys Alternatives Immunovant Alternatives Penumbra Alternatives Stevanato Group Alternatives iRhythm Technologies Alternatives Bausch + Lomb Alternatives Glaukos Alternatives TransMedics Group Alternatives Envista Alternatives LivaNova Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SLNO) was last updated on 10/5/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredMelt-up warning Porter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | SponsoredThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Soleno Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Soleno Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
